The path from target identification to IND filing involves decisions at each stage that determine whether a program reaches the clinic on schedule or stalls. This FAQ breaks down what that timeline actually looks like, where the critical decision points fall, and how Nona Biosciences’ integrated approach addresses the most common sources of delay.
What does a target-to-IND timeline actually include?
A complete target-to-IND program covers six major phases: target validation and antigen preparation, animal immunization, antibody screening and hit identification, lead selection and engineering, developability assessment, and IND-enabling preclinical studies including CMC and toxicology. Each phase has defined inputs and outputs, and delays in any one phase compound downstream. These phases are most efficiently executed in an integrated workflow rather than handed off sequentially between disconnected vendors.
How long does the immunization phase take, and why does it matter so much?
Immunization typically requires 2 months to generate a high-quality immune response with measurable, high-affinity antibody titers. Rushing this phase to 3 weeks produces unknown titers and risks entering screening with a suboptimal immune repertoire, which wastes time and budget at every downstream step. Nona advocates for the full 2-month protocol precisely because the quality of the immune response determines the diversity and affinity of the antibody pool available for screening.
What screening technologies are available, and how do they affect timeline?
Single B-cell (SBC) cloning compresses the screening phase to approximately 1 month, compared to 2 to 3 months for traditional hybridoma methods. Nona’s NonaCarFx™ platform adds a functional dimension to high-throughput screening, combining the speed of Beacon®-style platforms with throughput comparable to phage display (100,000 to 300,000 sequences per run, scalable to millions) and the ability to run function-based assays in the same workflow. This matters because identifying functionally active binders early eliminates candidates that would fail later in lead optimization, reducing total program time.
Is there a difference between fully human and humanized antibodies, and does it affect IND timelines?
Fully human antibodies carry 100% human sequence, produced in vivo through natural immune selection. Humanized antibodies are non-human sequences that have been engineered to reduce immunogenicity but still carry residual non-human residues and the engineering trade-offs that come with them. For IND timelines, understanding the fully human vs humanized monoclonal antibody distinction is consequential: fully human sequences sourced from Harbour Mice® (transgenic mice engineered to produce fully human antibodies in both H2L2 and heavy-chain-only HCAb formats) reduce the need for extensive re-engineering steps before IND-enabling studies, directly shortening the lead optimization phase and lowering immunogenicity risk in preclinical safety packages.
When should a program choose HCAb format versus conventional H2L2?
The choice depends on the therapeutic modality and downstream manufacturing requirements. The table below summarises the key decision factors:
|
Factor |
Fully Human (Harbour Mice®) |
H2L2 Format |
|---|---|---|
|
Molecular size |
Compact VH domain (~15 kDa, per scFv/VHH size comparisons in the literature) |
Full IgG format (~150 kDa conventional antibody) |
|
Bispecific manufacturing |
No chain mispairing risk |
Chain mispairing produces inconsistent results |
|
ADC applications |
Enables renal clearance at <40 kDa total |
Standard ADC format |
|
Sequence origin |
Fully human VH, naturally selected |
Fully human H2L2, naturally selected |
|
Clinical validation |
Multiple molecules in clinic |
Established format across industry |
For bispecific and multispecific programs, chain mispairing is the central manufacturing problem: when two different heavy chains and two different light chains are combined, the resulting product mixture contains mismatched species that reduce yield and complicate purification. HCAb-derived binders eliminate light chains entirely, removing the mispairing problem at its source.
What is the Idea toward IND® (I-to-I®) pathway and how does it differ from using multiple CROs?
I-to-I® (Nona’s integrated end-to-end service pathway from ideation through IND filing) covers the full program arc under a single scientific and operational framework, from target validation through IND submission. The practical difference versus assembling multiple CROs is that handoff risk, timeline slippage at vendor transitions, and data format incompatibilities are eliminated. Nona’s model also involves consultative project design rather than execution against a pre-written plan, meaning the workflow adapts when biology requires it rather than forcing a program into a fixed menu of options.
How does IP ownership work, and why does it affect program planning from day one?
Nona’s target-to-IND programs use a fee-for-service model with a single milestone payment tied to IND approval, giving clients full IP ownership and freedom to operate (FTO) without royalties or ongoing financial obligations. In contrast, some competitors incorporate multiple milestone payments or downstream royalties, and certain platforms include post-IND fees linked to underlying technologies, which can add complexity and long-term cost. For customers, this difference is important: cleaner, more transparent financial structures help preserve asset value, simplify future partnering or M&A, and avoid unexpected obligations later in development.
What are the most common sources of delay between lead selection and IND filing?
The three most frequently cited delay sources in the lead-to-IND phase are: extended lead optimization caused by poor hit quality from screening (addressable by investing in the immunization and screening phases), CMC timeline uncertainty when manufacturing is outsourced to a separate vendor without integrated oversight, and toxicology package gaps that require additional studies before IND submission.
Nona’s integrated CMC platform accelerates development from candidate selection to clinical supply, reducing risks and timelines. Additionally, Nona’s integrated Toxicology enables early Go/no-Go decisions, while broad in vivo capabilities and secured NHP access fast-track IND.
How does V-gene selection strategy affect antibody quality and downstream timelines?
Nona intentionally selects specific, highly developable V genes rather than using all available human V genes. For HCAb programs, this means 9 curated VH genes; for H2L2 programs, 19. Competitors which operate all human V genes expose the animal’s immune resources to non-viable options, producing screening pools where the majority of hits carry poor developability profiles. Filtering out those candidates consumes time and budget in lead optimization that a curated selection strategy avoids. The result is a higher proportion of viable leads entering the engineering phase, which directly compresses the time between screening completion and IND-enabling study initiation.
What clinical evidence supports Nona’s platform?
Nona has multiple molecules that have reached clinical stage, backed by partnerships with major pharmaceutical companies including Pfizer. These real-world programs represent validated execution of the same integrated workflow described above, not projected benchmarks. For teams evaluating whether the timeline is realistic for their specific target class — including those customizing programs for antibody-drug conjugate (ADC) development from discovery to IND — Nona’s scientific team can map prior program data against the proposed indication and modality.
If your program is at target identification and you want a stage-by-stage assessment of where your specific timeline risks sit, Nona’s team can review your target profile and modality requirements against our fully human antibody discovery workflow to identify where acceleration is possible without compromising the quality of your IND package.
-
Schardt J.S. et al., Discovery and characterization of high-affinity, potent SARS-CoV-2 neutralizing antibodies via single B cell screening, Scientific Reports, 2021. Link
-
Josephides D. et al., Rapid single B cell antibody discovery using nanopens and structured light, mAbs, 2019. Link
-
Harding F.A. et al., The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions, mAbs, 2010. Link
-
Liang S. & Zhang C., Prediction of immunogenicity for humanized and full human therapeutic antibodies, PLOS ONE, 2020. Link
-
Drabek D. et al., Expression Cloning and Production of Human Heavy-Chain-Only Antibodies from Murine Transgenic Plasma Cells, Frontiers in Immunology, 2016. Link
-
Drabek D. et al., A Transgenic Heavy Chain IgG Mouse Platform as a Source of High Affinity Fully Human Single-Domain Antibodies for Therapeutic Applications, Methods in Molecular Biology, 2022. Link
-
Labrijn A.F. et al., Bispecific antibodies: a mechanistic review of the pipeline, Nature Reviews Drug Discovery, 2019. Link
-
Shi Y. et al., Characterization and Monitoring of a Novel Light-heavy-light Chain Mispair in a Therapeutic Bispecific Antibody, Journal of Pharmaceutical Sciences, 2021. Link
-
Sormanni P. et al., Best practices for machine learning in antibody discovery and development, Drug Discovery Today, 2024. Link
-
Liu G. et al., Deep learning in preclinical antibody drug discovery and development, Methods, 2023. Link
-
Drabek D. et al., High-efficacy, high-manufacturability human VH domain antibody therapeutics from transgenic sources, Protein Engineering Design and Selection, 2021. Link
